A new study published in the journal of BMC Nephrology showed that hemodialysis patients with end-stage renal disease (ESRD) ...

Patients taking Kerendia saw significant reduction in cardiovascular death and hospitalization and urgent visits for heart ...

The US Food and Drug Administration (FDA) has granted 510(k) clearance for Tempus AI’s ECG-Low (ejection fraction) EF ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

Researchers at the German Center for Cardiovascular Research (DZHK) have identified a key molecule involved in a form of ...

The new Tempus software analyzes resting, non-ambulatory 12-lead ECG recordings to detect signs associated with having a low ...

Tempus AI Inc (NASDAQ:TEM) shares are trading higher Wednesday after the company announced that it received 510(k) clearance ...

Medically reviewed by Christopher Lee, MDSystolic congestive heart failure, or systolic heart failure, is a type of heart ...

The approval was supported by data from the randomized, double-blind, placebo-controlled, event-driven phase 3 FINEARTS-HF study.

The era of predictive modeling enhanced with machine learning and artificial intelligence (AI) to aid clinical ...

With an ejection fraction of 40 to 50 percent, patients may still compensate reasonably well and function fairly normally. Below 40 percent signifies heart failure, which can produce such symptoms ...

Is the ejection fraction on the way out as a way to direct medical therapy in patients with heart failure? Emotions are said to be high on both sides of the question.